Evaluation of intraocular pressure elevation after multiple injections of intravitreal ranibizumab

Alice L Yu,1,* Florian Seidensticker,1,* Markus Schaumberger,1 Ulrich Welge-Lussen,2 Armin Wolf11Department of Ophthalmology, Ludwig-Maximilians-University, Munich, Germany; 2Department of Ophthalmology, Friedrich-Alexander-University, Erlangen, Germany*These authors contributed equally to this wor...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yu AL, Seidensticker F, Schaumberger M, Welge-Lussen U, Wolf A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/82ca0aaaef8743689f82207e2f31d7cf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:82ca0aaaef8743689f82207e2f31d7cf
record_format	dspace
spelling	oai:doaj.org-article:82ca0aaaef8743689f82207e2f31d7cf2021-12-02T00:06:20ZEvaluation of intraocular pressure elevation after multiple injections of intravitreal ranibizumab1177-5483https://doaj.org/article/82ca0aaaef8743689f82207e2f31d7cf2014-04-01T00:00:00Zhttp://www.dovepress.com/evaluation-of-intraocular-pressure-elevation-after-multiple-injections-a16439https://doaj.org/toc/1177-5483 Alice L Yu,1,* Florian Seidensticker,1,* Markus Schaumberger,1 Ulrich Welge-Lussen,2 Armin Wolf11Department of Ophthalmology, Ludwig-Maximilians-University, Munich, Germany; 2Department of Ophthalmology, Friedrich-Alexander-University, Erlangen, Germany*These authors contributed equally to this workBackground: We wanted to determine whether multiple injections of intravitreal ranibizumab was associated with an elevated intraocular pressure (IOP) in patients treated for neovascular age-related macular degeneration (AMD).Methods: This retrospective study examined 53 patients with neovascular AMD treated with multiple injections of intravitreal ranibizumab. The main outcome measure was the difference in IOP between the frequently-treated study eyes (≥15 injections) and the unfrequently-treated fellow control eyes (≤ five injections). Patients were divided into three study groups: group I (35 patients with 15 to 19 injections); group II (15 patients with 20 to 29 injections); and group III (three patients with ≥30 injections). The IOP was measured by Goldmann applanation tonometry 4 weeks after the last injection of intravitreal ranibizumab. For statistical analysis, the IOP was then correlated with the number of ranibizumab injections.Results: Among the frequently-treated study eyes, the mean IOP was 13.68±2.91 mmHg (range, 8 to 20 mmHg). The unfrequently-treated fellow control eyes had a mean IOP of 13.45±3.09 mmHg (range, 9 to 25 mmHg). There was no significant correlation of the IOP difference between the study and control eyes with the number of ranibizumab injections (correlation coefficient 0.77; P=0.583). For each of groups I, II, and III, the difference in mean IOP between the study and control eyes was nonsignificant (P>0.05). There was also no significant association of the IOP difference between the study and control eyes with the number of ranibizumab injections for each group (P=0.391).Conclusion: Our study did not find an increased IOP in frequently-ranibizumab-treated eyes when compared to unfrequently-treated fellow control eyes. Further studies with a greater sample size are needed to evaluate whether an increased number of ranibizumab injections is associated with IOP changes.Keywords: age-related macular degeneration, ocular hypertension, anti-VEGF therapyYu ALSeidensticker FSchaumberger MWelge-Lussen UWolf ADove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2014, Iss default, Pp 743-747 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Yu AL Seidensticker F Schaumberger M Welge-Lussen U Wolf A Evaluation of intraocular pressure elevation after multiple injections of intravitreal ranibizumab
description	Alice L Yu,1,* Florian Seidensticker,1,* Markus Schaumberger,1 Ulrich Welge-Lussen,2 Armin Wolf11Department of Ophthalmology, Ludwig-Maximilians-University, Munich, Germany; 2Department of Ophthalmology, Friedrich-Alexander-University, Erlangen, Germany*These authors contributed equally to this workBackground: We wanted to determine whether multiple injections of intravitreal ranibizumab was associated with an elevated intraocular pressure (IOP) in patients treated for neovascular age-related macular degeneration (AMD).Methods: This retrospective study examined 53 patients with neovascular AMD treated with multiple injections of intravitreal ranibizumab. The main outcome measure was the difference in IOP between the frequently-treated study eyes (≥15 injections) and the unfrequently-treated fellow control eyes (≤ five injections). Patients were divided into three study groups: group I (35 patients with 15 to 19 injections); group II (15 patients with 20 to 29 injections); and group III (three patients with ≥30 injections). The IOP was measured by Goldmann applanation tonometry 4 weeks after the last injection of intravitreal ranibizumab. For statistical analysis, the IOP was then correlated with the number of ranibizumab injections.Results: Among the frequently-treated study eyes, the mean IOP was 13.68±2.91 mmHg (range, 8 to 20 mmHg). The unfrequently-treated fellow control eyes had a mean IOP of 13.45±3.09 mmHg (range, 9 to 25 mmHg). There was no significant correlation of the IOP difference between the study and control eyes with the number of ranibizumab injections (correlation coefficient 0.77; P=0.583). For each of groups I, II, and III, the difference in mean IOP between the study and control eyes was nonsignificant (P>0.05). There was also no significant association of the IOP difference between the study and control eyes with the number of ranibizumab injections for each group (P=0.391).Conclusion: Our study did not find an increased IOP in frequently-ranibizumab-treated eyes when compared to unfrequently-treated fellow control eyes. Further studies with a greater sample size are needed to evaluate whether an increased number of ranibizumab injections is associated with IOP changes.Keywords: age-related macular degeneration, ocular hypertension, anti-VEGF therapy
format	article
author	Yu AL Seidensticker F Schaumberger M Welge-Lussen U Wolf A
author_facet	Yu AL Seidensticker F Schaumberger M Welge-Lussen U Wolf A
author_sort	Yu AL
title	Evaluation of intraocular pressure elevation after multiple injections of intravitreal ranibizumab
title_short	Evaluation of intraocular pressure elevation after multiple injections of intravitreal ranibizumab
title_full	Evaluation of intraocular pressure elevation after multiple injections of intravitreal ranibizumab
title_fullStr	Evaluation of intraocular pressure elevation after multiple injections of intravitreal ranibizumab
title_full_unstemmed	Evaluation of intraocular pressure elevation after multiple injections of intravitreal ranibizumab
title_sort	evaluation of intraocular pressure elevation after multiple injections of intravitreal ranibizumab
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/82ca0aaaef8743689f82207e2f31d7cf
work_keys_str_mv	AT yual evaluationofintraocularpressureelevationaftermultipleinjectionsofintravitrealranibizumab AT seidenstickerf evaluationofintraocularpressureelevationaftermultipleinjectionsofintravitrealranibizumab AT schaumbergerm evaluationofintraocularpressureelevationaftermultipleinjectionsofintravitrealranibizumab AT welgelussenu evaluationofintraocularpressureelevationaftermultipleinjectionsofintravitrealranibizumab AT wolfa evaluationofintraocularpressureelevationaftermultipleinjectionsofintravitrealranibizumab
_version_	1718403938079735808

Evaluation of intraocular pressure elevation after multiple injections of intravitreal ranibizumab

Ejemplares similares